What is HC Wainwright’s Estimate for Vericel Q4 Earnings?

Vericel Corporation (NASDAQ:VCEL) – Equities researchers at HC Wainwright increased their Q4 2026 earnings per share (EPS) estimates for Vericel in a research report issued on Friday, July 31st. HC Wainwright analyst S. Ramakanth now anticipates that the biotechnology company will post earnings per share of $0.50 for the quarter, up from their prior forecast of $0.46. HC Wainwright currently has a “Buy” rating and a $70.00 target price on the stock. The consensus estimate for Vericel’s current full-year earnings is $0.54 per share. HC Wainwright also issued estimates for Vericel’s Q2 2027 earnings at $0.14 EPS, Q3 2027 earnings at $0.12 EPS and Q4 2027 earnings at $0.52 EPS.

A number of other research analysts have also recently weighed in on the stock. TD Cowen raised their price objective on shares of Vericel from $55.00 to $58.00 and gave the stock a “buy” rating in a research note on Friday. Truist Financial reaffirmed a “buy” rating and issued a $58.00 target price (up from $54.00) on shares of Vericel in a research note on Friday, July 31st. Wall Street Zen upgraded Vericel from a “hold” rating to a “buy” rating in a report on Saturday, July 18th. Canaccord Genuity Group set a $60.00 price target on Vericel in a research report on Thursday, July 30th. Finally, Weiss Ratings raised Vericel from a “sell (d+)” rating to a “hold (c)” rating in a report on Friday. Four analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat.com, Vericel has a consensus rating of “Moderate Buy” and an average target price of $58.40.

Vericel Trading Up 0.6%

Shares of VCEL opened at $46.34 on Monday. Vericel has a 12-month low of $28.95 and a 12-month high of $49.32. The stock has a market cap of $2.37 billion, a P/E ratio of 98.60 and a beta of 1.06. The company has a 50-day moving average of $42.41 and a two-hundred day moving average of $37.52.

Vericel (NASDAQ:VCEL) last released its quarterly earnings data on Thursday, July 30th. The biotechnology company reported $0.04 EPS for the quarter, topping the consensus estimate of ($0.03) by $0.07. The business had revenue of $77.46 million for the quarter, compared to analyst estimates of $72.70 million. Vericel had a net margin of 7.91% and a return on equity of 6.91%. The business’s revenue for the quarter was up 22.5% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.01) EPS.

Institutional Investors Weigh In On Vericel

Hedge funds have recently made changes to their positions in the business. Kestra Advisory Services LLC acquired a new position in Vericel in the fourth quarter valued at $27,000. Quarry LP acquired a new stake in Vericel in the 4th quarter worth about $31,000. Farther Finance Advisors LLC boosted its stake in Vericel by 116.5% in the 4th quarter. Farther Finance Advisors LLC now owns 970 shares of the biotechnology company’s stock worth $35,000 after buying an additional 522 shares during the last quarter. Truvestments Capital LLC grew its holdings in Vericel by 175.4% in the 4th quarter. Truvestments Capital LLC now owns 1,534 shares of the biotechnology company’s stock valued at $55,000 after buying an additional 977 shares during the period. Finally, Empowered Funds LLC purchased a new stake in Vericel in the 4th quarter valued at about $58,000.

Insider Activity

In other Vericel news, insider Jonathan Siegal sold 4,500 shares of Vericel stock in a transaction that occurred on Thursday, July 30th. The shares were sold at an average price of $48.90, for a total value of $220,050.00. Following the completion of the sale, the insider directly owned 1,078 shares of the company’s stock, valued at approximately $52,714.20. The trade was a 80.67% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Jonathan Mark Hopper sold 10,000 shares of the business’s stock in a transaction on Friday, June 26th. The shares were sold at an average price of $45.00, for a total value of $450,000.00. Following the completion of the transaction, the insider owned 75,753 shares of the company’s stock, valued at $3,408,885. This trade represents a 11.66% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders sold 52,232 shares of company stock worth $2,304,217. 7.60% of the stock is currently owned by corporate insiders.

Key Vericel News

Here are the key news stories impacting Vericel this week:

• Positive Sentiment: HC Wainwright maintained its Buy rating and $70 price target, implying substantial upside from recent trading levels. The firm projects earnings growth from $0.68 per share in fiscal 2027 to $1.13 in 2028, $1.61 in 2029 and $2.21 in 2030, suggesting confidence in Vericel’s long-term growth potential.
• Positive Sentiment: Truist Financial reiterated its Buy rating on Vericel, adding to the positive analyst backdrop. Vericel’s Buy Rating Reiterated at Truist Financial
• Neutral Sentiment: HC Wainwright’s longer-term earnings outlook remains constructive, but its estimates indicate that profitability may build gradually rather than accelerate immediately. The analyst expects a $0.13-per-share loss in the first quarter of 2027 before earnings improve in subsequent years.
• Negative Sentiment: HC Wainwright reduced its Q3 2026 EPS forecast to $0.02 from $0.12, its Q1 2027 forecast to a $0.13 loss from a $0.10 loss, and its fiscal 2027 forecast to $0.68 from $0.73. These cuts point to softer near-term results and could weigh on the stock despite the unchanged Buy rating and $70 target.

Vericel Company Profile

Vericel Corporation is a biotechnology company specializing in the development, manufacturing and commercialization of cell-based therapies for patients with severe diseases and conditions. The company’s expertise lies in regenerative medicine, where it harnesses the power of autologous cell processing to create products designed to restore function and promote healing in damaged tissues.

Vericel currently markets two FDA-approved therapies. MACI® (autologous cultured chondrocytes on porcine collagen membrane) is indicated for the repair of symptomatic cartilage defects of the knee in adult patients.